News und Analysen
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Andy Schmeltz, SVP Commercial Strategy & Innovation, and Navin Katyal, U.S. Commercial &
Simulations Plus Releases Redesigned NAFLDsym® QSP Software Tool
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the release of NAFLDsym v2B Beta, a
Agilent Announces New NovoCyte Flow Cytometer System Software for 21 CFR Part 11 Compliance
Agilent Technologies Inc. (NYSE: A) today announced the release of new NovoExpress software that introduces integrated compliance tools for NovoCyte flow cytometer systems. The compliance-enabling
Lonza Prices CHF 300 Million Straight Bond with a 2.100% Coupon
Humana and ChenMed Announce Five-Year Network Agreement
ChenMed, one of the largest senior-focused primary care providers in the United States, and leading health and well-being company Humana Inc. (NYSE: HUM) have signed a new five-year agreement
Sartorius Stedim Biotech SA: Board of Directors of Sartorius Stedim Biotech resolves to propose a dividend of 1.44 euros per share to the Annual Shareholders’ Meeting
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on February 6, 2023, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement
Xencor to Present at the SVB Securities Global Biopharma Conference
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that
Vistagen Provides Corporate Update and Reports Fiscal 2023 Third Quarter Financial Results
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system
Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year Financial and Operational Results on February 28, 2023
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for fourth quarter and full year 2023 on Tuesday
Humana Healthy Horizons to Support Maternal Health of Black Moms in Kentucky via Programs, Grants
Humana Healthy Horizons in Kentucky, Humana’s (NYSE: HUM) Kentucky Medicaid Plan, is pleased to announce that three local community-based organizations will receive grants totaling $120,000 from
Premier, Inc. Reports Fiscal-Year 2023 Second-Quarter Results
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today reported financial results for the fiscal year 2023 second quarter ended December 31, 2022. The
STAAR Surgical to Report Fourth Quarter and Fiscal Year Results on February 21, 2023
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, announced that
Vistagen to Report Fiscal Year 2023 Third Quarter Financial Results on February 7, 2023
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
NanoString Showcases Ultra High-Plex 6K RNA Single Cell Imaging at the 2023 Advances in Genome Biology and Technology (AGBT)
NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced an update to the technology roadmap for the CosMx™
Vistagen Announces Closing of Pherin Pharmaceuticals Acquisition
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous
Weill Cornell Medicine and NanoString Collaborate to Create Comprehensive Spatial Atlas of Human Anatomy
NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, announced the launch of the Spatial Atlas of Human Anatomy (SAHA)
Puma Biotechnology’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Breast Cancer with a HER2 Mutation
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for
EQS-News: Lausanne University Hospital Investigates Use of PENTIXAFOR in Cardio-Vascular Setting
EQS-News: Lausanne University Hospital Investigates Use of PENTIXAFOR in Cardio-Vascular Setting
ABIVAX: NOTICE TO HOLDERS OF BONDS CONVERTIBLE AND/OR EXCHANGEABLE INTO NEW AND/OR EXISTING SHARES (OCEANES) WITH A NOMINAL VALUE OF EUR 24,999,975.99
PFIZER REPORTS RECORD FULL-YEAR 2022 RESULTS AND PROVIDES FULL-YEAR 2023 FINANCIAL GUIDANCE
Pfizer Inc. (NYSE: PFE) reported exceptional financial results for fourth-quarter and full-year 2022 and provided 2023 financial guidance(4).
The fourth-quarter 2022 earnings presentation and
PFIZER REPORTS RECORD FULL-YEAR 2022 RESULTS AND PROVIDES FULL-YEAR 2023 FINANCIAL GUIDANCE
Pfizer Inc. (NYSE: PFE) reported exceptional financial results for fourth-quarter and full-year 2022 and provided 2023 financial guidance(4).
The fourth-quarter 2022 earnings presentation and